Sepsis is a systemic proinflammatory response caused by bacterial, fungal, viral, autoimmune diseases causing dysfunction of one or more organs or systems. In this context, the aim of this study was to compile the literature on the impact of implementing the sepsis protocol on lower mortality and morbidity, to elucidate risk factors and possible interventions. A total of 55 studies were identified according to our search strategy. After applying the adopted inclusion and exclusion criteria, a total of 31 studies in Medline/Pubmed and Medline/BVS were excluded. Then the titles, abstracts and the full text were read, 20 of the 24 references were excluded based on the eligibility criteria. Thus, 4 references were selected for full text evaluation. Finally, four articles were eligible for qualitative evaluation. Despite the early institution of therapeutic measures advocated in the international literature, mortality from sepsis in the institution in question is still high. All references demonstrate the association of better prognosis for early diagnosis of sepsis with respect to protocol adoption, with P-value lower than the significance level = 0.05. This review corroborates that there are still gaps in the treatment of sepsis. However, the implementation of this protocol allows for a better diagnosis of sepsis, reduces possible early sepsis diagnoses, and promotes the effective use of antimicrobial agents in this population. Therefore, we need to investigate more closely the associated risk factors and the implementation of sepsis protocols to obtain a possible effective intervention.

Bupropion is an antidepressant that has noradrenergic and dopaminergic effects, being a weak dopamine reuptake inhibitor. increasingly used as an adjuvant for the treatment of depression, which is rarely used in monotherapy. In this context, the aim of this study was to compile the literature and compare the effectiveness of the norepinephrine-dopamine reuptake inhibitor bupropion with selective serotonin reuptake inhibitors in the treatment of major depressive disorder. Sungo the results, which was performed and 147 patients, with an average age of 41.7 years, dividing them into three groups randomly to be treated with a different drug, the first with bupropion with 51 patients, the second with sertraline with 58 patients and the third with venlafaxine 65 patients. Regarding the rate of remission of symptoms, there was no statistical difference between the groups at week 10 of treatment. This review corroborates that there is a benefit of bupropion as an adjuvant in the treatment of patients who have depressive disorder and bipolar affective disorder. However, bupropion showed excellent results associated with antidepressants compared to other treatments with monotherapy, which did not reduce 50% of the Montgomery-Asberg depression scale score.